慢性粒细胞白血病患者Wnt5a基因及NPM1基因的表达及其意义

Expression and significance of Wnt5agene and NPM1 gene in chronic myeloid leukemia patients

目的:通过检测慢性粒细胞白血病的骨髓细胞中Wnt5a基因及NPM1基因的表达,探讨其相关性及意义。方法:选择在本院住院的慢性粒细胞白血病患者60例作为实验组,包括急变期、加速期、慢性期各20例,良性血液病患者60例作为对照组,培养骨髓细胞,通过RT-PCR方法进行检测,分析Wnt5a基因及NPM1基因的表达及其意义。结果:实验组三个亚组与对照组比较,Wnt5amRNA半定量均值、阳性率均较低,NPM1mRNA阳性率、中位表达水平均较高,差异有统计学意义(P<0.05);实验组三个亚组中,急变期与加速期、慢性期间比较,Wnt5amRNA半定量均值、阳性率均较低,NPM1mRNA阳性率、中位表达水平均较高,差异有统计学意义(P<0.05);Wnt5a、NPM1的表达水平与患者的白细胞计数、骨髓原始细胞数相关,差异有统计学意义(P<0.05);与年龄、血红蛋白含量、血小板计数无关,差异无统计学意义(P>0.05)。结论:Wnt5a基因及NPM1基因与慢性粒细胞白血病的发生、发展有一定的相关性,Wnt5a基因可能抑制其发生,而NPM1基因阳性促进其进展,这可能成为慢性粒细胞白血病诊断、治疗、分析预后的新方式,为临床提供理论依据。

Objective： To explore the expression and significance of Wnt5a gene and NPM1 gene in chronic myeloid leu- kemia bone marrow cells. Methods： A total of 60 cases with chronic myeloid leukemia were selected as the experimental group, including 20 cases at acute phase, 20 cases at accelerated phase, 20 cases at chronic phase. And another 60 cases with benign hematologic diseases were selected as the control group. Bone marrow cells were cultured and detected by RT-PCR to detect expression of Wnt5a gene and NPM1 gene. Results： Compared with control group, semiquantitative mean level and positive rate of WntSa mRNA in three sub--groups of the control group were significantly low; positive rate and the median expression level of NPM1 mRNA were significantly higher（P〈0.05） ;semiquantitative mean level and positive rate of WntSa mRNA in a- cute phase group was significantly lower than the other two subgroups, positive rate and the median expression level of NPM1 mRNA were significantly higher（P〈0. 05）;White blood cell count and bone marrow cells were significanly associated with Wnt5a, NPM1 expression levels （P〈0.05）; but age, hemoglobin and platelet count had no correlation with Wnt5a, NPM1 expression levels（P〈0.05）. Conclusions： Wnt5a gene and NPM1 gene are correlated with chronic myeloid leukemia. Wnt5a gene may inhibit its occurrence, and NPM1 gene may promote its progress, which may be new target of treatment for chronic myeloid leukemia.